Targeting WEE1 Kinase in Gynecological Malignancies [PDF]
Drug Design, Development and TherapyWenhao Zhang,1,2 Qingli Li,1,2,* Rutie Yin1,2,* 1Department of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University, Chengdu, People’s Republic of China; 2Key Laboratory of Birth Defects and Related Diseases of ...
Zhang W, Li Q, Yin R
doaj +4 more sources
Pharmacological Inhibition of Wee1 Kinase Selectively Modulates the Voltage-Gated Na+ Channel 1.2 Macromolecular Complex [PDF]
Cells, 2021 Voltage-gated Na+ (Nav) channels are a primary molecular determinant of the action potential (AP). Despite the canonical role of the pore-forming α subunit in conferring this function, protein–protein interactions (PPI) between the Nav channel α subunit ...
Nolan M. Dvorak +5 more
doaj +2 more sources
GCN2 is a determinant of the response to WEE1 kinase inhibition in small-cell lung cancer [PDF]
Cell ReportsSummary: Patients with small-cell lung cancer (SCLC) are in dire need of more effective therapeutic options. Frequent disruption of the G1 checkpoint in SCLC cells creates a dependency on the G2/M checkpoint to maintain genomic integrity.
Alexandros P. Drainas +9 more
doaj +2 more sources
WEE1 kinase is a therapeutic vulnerability in CIC-DUX4 undifferentiated sarcoma [PDF]
JCI Insight, 2022 CIC-DUX4 rearrangements define an aggressive and chemotherapy-insensitive subset of undifferentiated sarcomas. The CIC-DUX4 fusion drives oncogenesis through direct transcriptional upregulation of cell cycle and DNA replication genes.
Rovingaile Kriska M. Ponce +4 more
doaj +2 more sources
WEE1 kinase inhibition to overcome acquired resistance to targeted therapies in colorectal cancer [PDF]
EMBO Molecular MedicineMolecular therapies targeting the EGFR/MAPK pathway have improved outcomes in colorectal cancer (CRC), yet acquired resistance remains a major clinical challenge. Oncogenic signaling can activate stress response pathways that sustain tumor survival under
Kristi Buzo +18 more
doaj +2 more sources
Inhibition of WEE1 kinase and cell cycle checkpoint activation sensitizes head and neck cancers to natural killer cell therapies [PDF]
Journal for ImmunoTherapy of Cancer, 2018 Background Natural killer (NK) cells recognize and lyse target tumor cells in an MHC-unrestricted fashion and complement antigen- and MHC-restricted killing by T-lymphocytes.
Jay Friedman +8 more
doaj +2 more sources
WEE1 kinase inhibition reverses G2/M cell cycle checkpoint activation to sensitize cancer cells to immunotherapy [PDF]
OncoImmunology, 2018 Intrinsic resistance to cytotoxic T-lymphocyte (CTL) killing limits responses to immune activating anti-cancer therapies. Here, we established that activation of the G2/M cell cycle checkpoint results in tumor cell cycle pause and protection from ...
Lillian Sun +9 more
doaj +2 more sources
Targeting WEE1 Kinase for Breast Cancer Therapeutics: An Update [PDF]
International Journal of Molecular SciencesAnthony W Ashton +2 more
exaly +2 more sources
WEE1 Kinase Inhibitor AZD1775 Induces CDK1 Kinase-Dependent Origin Firing in Unperturbed G1- and S-Phase Cells [PDF]
Proceedings of the National Academy of Sciences of the United States of America, 2019 Tatiana N Moiseeva +2 more
exaly +2 more sources
Efficient induction of apoptosis by wee1 kinase inhibition in hepatocellular carcinoma cells. [PDF]
PLoS ONE, 2014 Transforming growth factor-β1 (TGF-β1) potently inhibits human hepatocellular carcinoma (HCC) cell growth. Here we demonstrated that TGF-β1-induced apoptosis is mediated by decreased phosphorylation of cdc2 at Tyr15 accompanied by down-regulation of Wee1
Tomomi Kogiso +5 more
doaj +1 more source